NEW YORK (GenomeWeb News) – The DNA Medicine Institute has won a Small Business Innovation Research contract worth $600,000 over two years from the National Aeronautics and Space Administration to develop nanoscale diagnostic assays for analyzing health from blood samples.

The for-profit firm, which bases its products on nanotechnology, genomics, and molecular biology among others, will use the Phase II funding to develop assays for assessment of bone loss, immune function, cardiac health, liver function, and lipid status.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.